Join Josie: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://joinjosie.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   ““The same active ingredient found in the FDA-approved brand Wegovy®.””

2. 2

   ““The same active ingredient found in the FDA-approved brand Zepbound®.””

3. 3

   “The compounded semaglutide and tirzepatide products displayed on your website identify “Join Josie” on the pictured label, suggesting Join Josie is the compounder of those drugs when in fact it is not.”

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

joinjosie.com returned a live storefront when we checked in August 2026, offering hormone replacement therapy, weight management and weight maintenance for perimenopause and menopause, and citing a membership figure. We did not review every page on the site.

This is the letter that shows a claim can be true sentence-by-sentence and still mislead. Every fact in "the same active ingredient found in the FDA-approved brand Wegovy®" checks out — and the approval in it belongs to Wegovy, not to the vial being sold. The registered symbol reinforces the effect, because a trademark signals a real, regulated product standing behind the words. For a reader weighing a menopause-care subscription against a brand prescription, the difference matters more than usual: these decisions are often made alongside hormone therapy, where "approved" and "compounded" also sit side by side and are also easy to blur. Nothing in the letter suggests the medication is ineffective or that the company handled anyone's care poorly. It says the credential in the sentence belongs to a different product than the one in the cart.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Join Josie failed to respond.